Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kumamoto
Clinical trial register · Japan

Clinical Trials in Kumamoto, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 Takeda10 Janssen Research & Development, LLC10 GlaxoSmithKline7 Daiichi Sankyo6
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Kumamoto

143 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Kurume-shi, Sapporo, Kumamoto, Kyoto, Matsumoto-shi, Suita-shi, Bunkyo-ku, Shinjuku-ku
2027-11-23
Not yet open
Takeda
Phase 2
36
Nagoya, Kumamoto, Shinjuku-ku, Niigata, Osaka
2026-10-15
Recruiting
AstraZeneca
Phase 3
1,500
Aira, Chūōku, Fukuoka, Hachioji-shi, Izunokuni-shi, Kumamoto, Nagoya, Nerima-ku
2026-08-20
Recruiting
Stemline Therapeutics, Inc.
Phase 2
70
Chiba, Fukuoka, Ina, Isehara, Kōtō City, Kumamoto, Nagoya, Osaka
2026-08-18
Recruiting
Alkermes, Inc.
Phase 3
150
Kumamoto
2026-08-13
Recruiting
Amgen
Phase 3
950
Matsuyama, Kitakyusyu-shi, Aki-gun, Mito, Naka, Tsuchiura-shi, Kumamoto, Kashiwara-shi
2026-07-29
Recruiting
AstraZeneca
Phase 3
600
Asahikawa-shi, Kamakura-shi, Kashiwa-shi, Kobe, Komoro, Kumamoto, Kyoto, Miyazaki
2026-07-08
Recruiting
AstraZeneca
Phase 3
900
Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi
2026-07-06
Recruiting
AstraZeneca
Phase 3
1,200
Asahikawa-shi, Chūōku, Kamakura-shi, Koga-shi, Kumamoto, Mitaka-shi, Mito, Miyazaki
2026-07-06
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
NCT07637734Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
Sapporo, Kamimashiki-gun, Kumamoto, Sakai, Saitama, Tokyo
2026-06-15
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
Kumamoto, Shinjuku-ku
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Fukuoka, Hachioji-shi, Hamamatsu, Hiroshima, Kakogawa-shi, Kumagaya-shi, Kumamoto, Matsusaka-shi
2026-06-11
Recruiting
Takeda
Phase 2
92
Fukuoka, Kumamoto, Isahaya-shi, Yodogawa-ku, Osaka-shi, Shinjuku-ku
2026-06-04
Recruiting
Pfizer
Phase 2
24
Saitama-shi, Kumamoto, Tokyo
2026-05-28
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Bunkyō City, Hamamatsu, Higashi-Ibaraki, Kagoshima, Kashiwa, Kumamoto, Minatoku, Mitaka
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bunkyō City, Hamamatsu, Hirosaki, Kagoshima, Kashiwa, Kobe, Kumamoto, Minatoku
2026-05-22
Recruiting
Eli Lilly and Company
Phase 2
531
Chūōku, Fujiidera, Isehara, Kobe, Kumamoto, Sapporo, Shinjuku-Ku
2026-05-06
Recruiting
Novo Nordisk A/S
Phase 3
300
Fukuoka, Hiroshima, Kumamoto, Okinawa, Osaka, Sapporo-shi, Hokkaido, Shizuoka, Tokyo
2026-05-05
Recruiting
Alkermes, Inc.
Phase 3
176
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-ku, Kumamoto, Tokyo
2026-04-22
Recruiting
Alkermes, Inc.
Phase 3
150
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-Ku, Kumamoto
2026-04-06
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
75
Ibaraki, Kitakyushu-shi, Kumamoto
2026-03-04
Recruiting
Eli Lilly and Company
Phase 2
450
Chikugo, Fukushima, Hachinohe, Hiratsuka, Karatsu, Kodaira, Kumamoto, Kurume
2026-02-10
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
Bunkyo C, Kumamoto, Matsumoto-shi, Suita
2026-02-03
Recruiting
Eli Lilly and Company
Phase 3
150
Abeno, Iruma, Kawasaki, Kofu, Kōriyama, Kumamoto, Nagano, Naka
2026-01-12
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Bunkyō City, Kumamoto, Kurume, Matsumoto, Sendai, Shinjuku, Suita, Tsukuba
2026-01-09
Not yet open
Kumamoto University
Not applicable
60
Kumamoto
2026-01
Active, closed
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-12-19
Recruiting
Pfizer
Phase 3
32,500
Nagoya, Iizuka-shi, Itoshima, Kitakyushu-shi, Onga-gun, Koga, Kumamoto, Ōmura
2025-12-10
Recruiting
AstraZeneca
Phase 2
230
Kochi, Kumamoto, Meguro-ku, Nagasaki, Shimonoseki-shi, Yaizu-shi
2025-12-10
Recruiting
GlaxoSmithKline
Phase 3
450
Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Kumamoto, Miyagi, Osaka
2025-12-03
Recruiting
Eli Lilly and Company
Phase 3
7,140
Chūōku, Hamadayama, Suginami-ku, Izumisano, Kobe, Kofu, Kumamoto, Shinjuku-ku, Takarazuka
2025-12-01
Active, closed
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-11-25
Recruiting
Eli Lilly and Company
Phase 2
400
Chikugo, Chiyoda City, Fukushima, Iruma, Karatsu, Kōtō City, Kumamoto, Kure
2025-11-24
Recruiting
AstraZeneca
Phase 3
420
Akashi, Bunkyō City, Himeji-shi, Kōtoku, Kumamoto, Matsumoto-shi, Matsuyama, Meguro-ku
2025-11-11
Recruiting
Daiichi Sankyo
Phase 3
686
Hidaka-shi, Hirakata-shi, Hirosaki-shi, Kashiwa-shi, Kawasaki-shi, Kitakyushu-shi, Kumamoto, Kurume-shi
2025-10-24
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 4
200
Bunkyō City, Kumamoto, Kurume-shi, Kyoto, Mitaka-shi, Nagoya, Nankoku-shi, Okayama
2025-10-01
Recruiting
Daiichi Sankyo
Phase 2/3
630
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kawasaki, Kōtoku, Kumamoto, Kyoto
2025-09-26
Recruiting
BeOne Medicines
Phase 3
500
Nagoya, Nakamuraku, Matsuyama, Fukushima, Hiroshima, Sapporo, Nankoku, Kumamoto
2025-09-04
Recruiting
AbbVie
Phase 1
135
Kashiwa-shi, Kumamoto, Mibu, Bunkyo-ku, Koto-ku
2025-08-07
Active, closed
GlaxoSmithKline
Phase 2
168
Aichi, Fukuoka, Hyōgo, Kumamoto, Okayama, Tokyo
2025-08-06
Recruiting
AstraZeneca
Phase 3
700
Bunkyō City, Fukuoka, Kamakura-shi, Kawagoe-shi, Kawasaki-shi, Kisarazu-shi, Kumamoto, Kyoto
2025-08-06
Recruiting
BioMarin Pharmaceutical
Phase 2
60
Kumamoto, Osaka, Tokyo, Tottori
2025-07-30
Recruiting
AbbVie
Phase 3
120
Ōbu, Kashiwa-shi, Kurume-shi, Maebashi, Kobe, Kumamoto, Saga, Saitama-shi
2025-07-28
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Bunkyō City, Fukuoka, Kagawa, Kashihara, Kobe, Kumamoto, Kurume, Matsumoto-shi
2025-07-02
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Nagoya, Sapporo, Kobe, Kamakura, Yokohama, Kumamoto, Chuo Ku, Chiba
2025-07-01
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bunkyō City, Fukuoka, Fukushima, Gifu, Kanazawa, Kobe, Kumamoto, Maebashi
2025-06-04
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
Kumamoto, Nagano
2025-05-12
Recruiting
Takeda
Phase 2
88
Kohoku-ku, Yokohama-Shi, Kumamoto, Isahaya-shi, Urasoe-Shi, Shinjuku-ku, Sumida-Ku, Fukuoka, Yodogawa-ku, Osaka-shi
2025-05-06
Recruiting
Takeda
Phase 3
59
Nagoya, Kumamoto, Sendai, Kashihara, Higashi-Matsuyama, Ōtsu, Tokushima, Bunkyo-ku
2025-05-06
Recruiting
Novo Nordisk A/S
Observational
630
Koriyama-shi, Fukushima, Oita-shi, Oita,, Kumamoto, Aichi, Aomori, Chiba, Chitose, Hokkaido, Ehime
2025-04-15
Active, closed
Amgen
Phase 3
1,105
Matsuyama, Kitakyusyu-shi, Aki-gun, Mito, Naka, Tsuchiura-shi, Kumamoto, Kashiwara-shi
2025-03-17
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Nagoya, Kashiwa, Nishinomiya, Kanazawa, Shibuya-ku, Fukuoka, Kumamoto, Okayama
2025-03-12
Recruiting
Summit Therapeutics
Phase 3
780
Nagoya, Kurume, Asahikawa, Nishinomiya, Kanazawa, Tokyo, Kumamoto, Kyoto
2025-02-27
Recruiting
Takeda
Phase 2
96
Fukuoka-Shi Hakata-Ku, Kurume-shi, Kohoku-ku, Yokohama-Shi, Kumamoto, Yodogawa-ku, Osaka-shi, Bunkyo-ku
2025-02-07
Recruiting
NovoCure GmbH
Phase 3
741
Toyoake-shi, Isehara, Fukuoka, Hokkaido, Ishikawa, Kumamoto, Kyoto, Mitaka
2025-02-03
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Chūōku, Kashihara-shi, Kōtoku, Kumamoto, Kurume-shi, Niigata, Osakasayama-shi, Sapporo
2025-01-29
Active, closed
Institut de Recherches Internationales Servier
Phase 1/2
51
Kumamoto, Kyoto, Nagoya, Tokyo
2025-01-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Yotsukaidō, Tsuchiura, Kiyose, Toshimaku, Fukuoka, Kumamoto
2024-12-02
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chiba, Kashiwa, Kōtoku, Kumamoto, Niigata, Okayama, Osaka, Yokohama
2024-11-27
Active, closed
Genmab
Phase 3
191
Matsuyama, Kitakyushu-shi, Hiroshima, Kobe, Kumamoto, Osakasayama-shi, Bunkyō City, Chūōku
2024-11-25
Active, closed
GlaxoSmithKline
Phase 2
283
Chiba, Hokkaido, Hyōgo, Kagawa, Kumamoto, Osaka, Tokyo, Yamanashi
2024-11-11
Active, closed
Amgen
Phase 2
409
Fukuoka, Mito, Tsuchiura-shi, Kumamoto, Nagasaki, Kashiwara-shi, Shizuoka, Meguro-ku
2024-11-07
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Fuchū, Kanazawa, Kobe, Kumamoto, Matsumoto, Saga, Yokohama
2024-10-29
Active, closed
Incyte Corporation
Phase 3
346
Bunkyō City, Inashiki-gun, Kamimashiki-gun, Kawasaki-shi, Kitakyushu, Kobe, Kumamoto, Minamikoshigaya
2024-10-10
Active, closed
AstraZeneca
Phase 3
768
Bunkyō City, Fukuoka, Hiroshima, Iruma-Gun, Iwakuni-shi, Kobe, Kōtoku, Kumamoto
2024-10-04
Recruiting
AstraZeneca
Phase 3
1,018
Bunkyō City, Chiba, Chuo-shi, Fukuoka, Hirakata-shi, Kobe, Kōtoku, Kumamoto
2024-08-07
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
60
Fukuoka, Kashiwa-shi, Kōtoku, Kumamoto
2024-08-07
Active, closed
GlaxoSmithKline
Phase 3
10,212
Hiroshima, Ibaraki, Kumamoto, Okinawa, Saitama, Shizuoka, Tokyo, Yamagata
2024-08-01
Recruiting
AstraZeneca
Phase 3
788
Chiba, Hidaka-shi, Hirakata-shi, Isehara-shi, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2024-08-01
Active, closed
Incyte Biosciences Japan GK
Phase 3
21
Aichi, Fukui, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto
2024-07-30
Recruiting
Daiichi Sankyo
Phase 1/2
123
Himeji-shi, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Nagaizumi-cho, Niigata, Okayama
2024-07-22
Active, closed
Novo Nordisk A/S
Observational
1,071
Tokyo, Kumamoto, Aichi, Akita, Akita-shi, Akita, Aomori, Bunkyo-ku, Tokyo, Chiba
2024-06-11
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Amagasaki Shi, Kawasaki Shi, Kobe, Kumamoto, Osaka, Ōta-ku, Saitama, Wakayama
2024-04-18
Active, closed
GlaxoSmithKline
Phase 4
1,358
Fukuoka, Gifu, Hiroshima, Hyōgo, Kagawa, Kagoshima, Kanagawa, Kumamoto
2024-04-16
Recruiting
AbbVie
Phase 1/2
76
Nagoya, Kumamoto, Shibuya-ku
2024-04-01
Recruiting
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
NCT06342414Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer
City of Hope Medical Center
Observational
400
Fukuoka, Kumamoto, Sapporo, Tokushima
2024-03-15
Active, closed
Janssen Pharmaceutical K.K.
Phase 3
19
Hokkaido, Ichinomiya, Itabashi Ku, Kitakyushu-shi, Kumamoto, Nagoya, Osaka, Sendai
2024-02-09
Active, closed
Janssen Research & Development, LLC
Phase 3
112
Fuchū, Kanazawa, Kobe, Kumamoto, Matsumoto, Saga, Setagaya Ku, Shinjuku
2024-01-19
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Bunkyō City, Kumamoto, Kurume-shi, Kyoto, Matsumoto-shi, Sapporo, Shinjuku-ku, Suita-shi
2024-01-11
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Nagoya, Hirosaki-Shi, Fukuoka, Sagamihara, Yokohama, Kumamoto, Sendai, Okayama
2023-12-18
Recruiting
Intellia Therapeutics
Phase 3
1,200
Kumamoto, Osaka, Tokyo, Toyama
2023-12-13
Recruiting
AbbVie
Phase 3
110
Ōbu, Kashiwa-shi, Kurume-shi, Maebashi, Kumamoto, Izumi-Shi, Saitama-shi, Bunkyo-ku
2023-12-11
Recruiting
BioMarin Pharmaceutical
Observational
400
Kumamoto, Suita, Yonago, Tokushima, Tokyo
2023-11-27
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1
189
Nagoya, Kashiwa, Matsuyama, Hiroshima, Kobe, Yokohama, Kumamoto, Sendai
2023-11-01
Active, closed
Servier
Phase 2
12
Kashiwa, Kumamoto, Matsuyama, Osaka, Sapporo, Tokyo, Yokohama
2023-10-10
Recruiting
Bristol-Myers Squibb
Observational
50
Toyokawa, Kumamoto
2023-10-06
By invitation
Biogen
Phase 3
306
Nagoya, Yoshida-gun, Kitakyushu-shi, Kakogawa-shi, Kanazawa, Kawasaki-shi, Yokohama, Kumamoto
2023-10-03
Active, closed
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
NCT06547528Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugONO-4685
Ono Pharmaceutical Co., Ltd.
Phase 1
108
Nagoya, Akita, Kashiwa-shi, Fukuoka, Sapporo, Isehara-shi, Kumamoto, Kyoto
2023-10-01
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Chūōku, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Osaka, Ōsaka-sayama, Sapporo
2023-08-18
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Shibukawa-shi, Kamakura-Shi, Kumamoto, Sunto-gun, Chiba, Gifu, Hiroshima, Isehara-shi
2023-06-22
Recruiting
Takeda
Phase 3
240
Kurume-Shi, Kumamoto, Hidaka, Bunkyo-Ku, Setagaya-Ku
2023-05-16
Active, closed
Servier Affaires Médicales
Phase 3
299
Kanagawa, Kumamoto, Matsuyama, Osaka, Sapporo, Tokyo
2023-05-03
Recruiting
Takeda
Phase 2/3
500
Kurume-Shi, Kumamoto, Nagasaki, Osaka, Bunkyo-Ku, Nagakute
2023-04-05
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Fuji-shi, Kanazawa, Kashihara-shi, Kisarazu-shi, Kobe, Kumamoto, Nagano, Nagasaki
2023-03-23
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Koriyama-shi, Fukushima, Koriyama-shi, Kumamoto, Chiba-shi, Chiba, Ehime, Ibaraki, Minato-ku, Tokyo, Mito-shi, Ibaraki
2023-03-01
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Nagoya, Osaka, Suita, Kofu, Kumamoto
2023-02-02
Active, closed
Daiichi Sankyo
Phase 3
1,170
Ehime, Fukoka, Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kanagawa, Kumamoto
2023-01-11
Active, closed
AstraZeneca
Phase 3
1,350
Bunkyō City, Chūōku, Hamamatsu, Hidaka-shi, Hirosaki-shi, Hiroshima, Kumamoto, Nagoya
2022-12-29
By invitation
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Kurume-Shi, Fukuoka, Hamamatsu, Kumamoto, Kurume, Matsumoto, Okayama, Osaka
2022-11-30
Active, closed
Hoffmann-La Roche
Phase 3
68
Fukuoka, Hyōgo, Kagoshima, Kumamoto, Osaka, Tokyo
2022-11-01
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 3
37
Kumamoto, Toyoake
2022-10-18
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Kumamoto, Yamagata
2022-07-22
Active, closed
Gilead Sciences
Phase 3
623
Aichi, Bunkyō City, Chūōku, Ehime, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2022-07-20
Recruiting
Toray Industries, Inc
Phase 1/2
49
Nagoya, Fukuoka, Sapporo, Kumamoto, Matsumoto, Niigata, Hidaka, Nagaizumi-chō
2022-07-06
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Shinjuku-ku, Fukuoka, Itabashi-ku, Kumamoto, Mitaka, Miyazaki, Sendai, Tsu
2022-06-30
Recruiting
Innovacell GmbH
Phase 3
290
Sapporo, Chiba, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kumamoto, Kyoto
2022-05-11
Active, closed
AstraZeneca
Phase 3
760
Chūōku, Fukuoka, Hiroshima, Kashihara-shi, Kashiwa, Kumamoto, Mitaka-shi, Morioka
2022-03-28
Active, closed
AstraZeneca
Phase 3
1,035
Chiba, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashihara-shi, Kita-gun, Kobe, Kumamoto
2022-03-25
Active, closed
Daiichi Sankyo
Phase 3
740
Aomori, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Kanazawa, Yokohama, Kumamoto
2022-03-04
Recruiting
Takeda
Phase 3
120
Kurume-Shi, Kumamoto, Bunkyo-Ku, Setagaya-Ku
2022-02-10
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Herceptin·Taxol
ALX Oncology Inc.
Phase 2/3
127
Chiba, Fukuoka, Gifu, Kumamoto, Kyoto, Nagasaki, Osaka, Ōita
2022-01-15
Active, closed
GlaxoSmithKline
Phase 2
360
Gifu, Hiroshima, Hokkaido, Ishikawa, Kagawa, Kumamoto, Miyagi, Niigata
2021-12-14
Active, closed
Taiho Pharmaceutical Co., Ltd.
Phase 1
78
Chiba, Hokkaido, Kumamoto, Osaka, Tokyo
2021-12-01
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Fukuoka, Gifu, Higashiibaraki-gun, Isehara, Kamakura-shi, Kashiwa, Koshigaya, Kumamoto
2021-10-14
Recruiting
Janssen Research & Development, LLC
Phase 3
199
Chiba, Hanamaki, Hiroshima, Itabashi Ku, Kawasaki Shi, Kita Gun, Kumamoto, Nagoya
2021-07-15
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3
434
Hokkaido, Kobe, Kumamoto, Kyoto, Nagasaki, Osaka, Saitama, Toyoake
2021-07-06
Active, closed
AstraZeneca
Phase 3
315
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Kitaadachi-gun, Kōtoku, Kumamoto, Matsuyama
2021-06-30
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Nagoya, Sapporo, Kobe, Yokohama, Kumamoto, Suita, Kitaadachi-gun, Bunkyo Ku
2021-06-09
Active, closed
Savara Inc.
Phase 3
164
Chiba, Sapporo, Yokohama, Kumamoto, Sendai, Sakai, Saitama, Mitaka
2021-05-19
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Aichi, Chiba, Chūō, Fukuoka, Kumamoto
2021-02-23
Active, closed
GlaxoSmithKline
Phase 3
1,720
Fukuoka, Kumamoto, Tokyo
2021-02-15
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Chiba, Fukuoka, Gifu, Hokkaido, Kobe, Koshigaya, Kumamoto, Kurashiki
2021-02-01
Active, closed
AstraZeneca
Phase 3
1,371
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Isehara-shi, Kitaadachi-gun, Kōtoku, Kumamoto
2021-01-28
Active, closed
Novartis Pharmaceuticals
Phase 2
24
Nagoya, Kashiwa, Isehara, Yokohama, Kumamoto, Sendai, Osaka, Suita
2021-01-08
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Fukushima, Kanazawa, Kashiwa-shi, Kita-ku, Kumamoto, Matsumoto-shi, Nagoya, Shibuya-ku
2020-11-03
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 2
25
Nagoya, Sagamihara, Sendai, Hidaka, Hiroshima, Kumamoto, Kyoto, Osaka
2020-07-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
6,033
Hachiōji, Fukuoka, Kumamoto, Osaka, Tokyo
2020-02-27
Active, closed
MitraClip EXPAND G4 Study
NCT04177394Mitral Valve Regurgitation, Mitral Regurgitation
Abbott Medical Devices
Observational
1,164
Nagoya, Gifu, Himeji, Tokyo, Kumamoto, Sendai, Okayama, Toyama
2020-01-17
Active, closed
Takeda
Phase 3
354
Toyoake-Shi, Kashiwa-Shi, Matsuyama, Sapporo, Kurume-Shi, Yokohama, Kumamoto, Natori-shi
2020-01-10
Active, closed
Institut de Recherches Internationales Servier
Phase 3
331
Nagoya, Toyoake, Minami-Ku, Bunkyō-Ku, Chuo Ku, Kumamoto, Kyoto, Okayama
2020-01-05
Active, closed
JCR Pharmaceuticals Co., Ltd.
Phase 2/3
27
Fukui, Fukuoka, Gifu, Hiroshima, Hokkaido, Kanagawa, Kumamoto, Okayama
2019-09-01
Active, closed
BeOne Medicines
Phase 3
510
Nagoya, Toyohashi, Chiba, Kurume, Hiroshima, Yokohama, Kumamoto, Kyoto
2019-08-20
Active, closed
AstraZeneca
Phase 3
923
Bunkyō City, Fukuoka, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku, Kumamoto
2019-06-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Nagoya, Kashiwa, Sapporo, Nishinomiya, Sagamihara, Kumamoto, Hidaka, Kitaadachi-gun
2018-12-27
Active, closed
AstraZeneca
Phase 3
1,063
Bunkyō City, Fukuoka, Hirosaki-shi, Hiroshima, Kanazawa, Kōtoku, Kumamoto, Miyazaki
2018-11-16
Active, closed
Hoffmann-La Roche
Phase 3
257
Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Kanagawa, Kumamoto
2018-08-16
Active, closed
Bristol-Myers Squibb
Phase 3
545
Kashiwa-shi, Kurume-shi, Sapporo, Nishinomiya-shi, Morioka, Kumamoto, Osaka, Ōsaka-sayama
2018-04-18
Active, closed
Sanofi
Phase 3
475
Nagoya, Higashiibaraki-gun, Konan-ku, Yokohama-shi, Kumamoto, Sendai, Okayama, Sunto-gun, Shibuya-ku
2017-12-07
Active, closed
AstraZeneca
Phase 3
1,324
Bunkyoku, Chiba, Fukuoka, Hiroshima, Iizuka, Kanazawa, Kōtoku, Kumamoto
2017-10-11
Active, closed
DS-3201b in Participants With Lymphomas
NCT02732275Lymphoma, Malignant, Non-hodgkin Lymphoma
DrugValemetostat Tosylate
Daiichi Sankyo Co., Ltd.
Phase 1
100
Nagoya, Kahiwa-shi, Morioka, Kagoshima, Kumamoto, Nagasaki, Nakagami-gun, Minato-ku
2016-03-31
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Fukuoka, Kanazawa, Kashiwa, Kita-Gun, Kumamoto, Kurume, Matsuyama, Miyazaki
2014-11-26
Active, closed
Kumamoto University
Phase 4
268
Kumamoto
2008-06
Recruiting
Manuel Monreal
Observational
120,000
Kitakyushu, Maebashi, Amagasaki, Kumamoto, Kyoto, Tsu, Nagasaki, Osaka
2001-03
Rows per page Showing 1–143 of 143
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kumamoto

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 143 of those studies with a site in Kumamoto.

How many clinical trials are recruiting in Kumamoto?

73 of the 143 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 3 have not yet opened recruitment, 65 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kumamoto), 143 studies
PhaseStudiesRecruitingShare
Phase 3914363.6%
Phase 2211314.7%
Observational865.6%
Phase 1724.9%
Phase 1/2644.2%
Phase 2/3533.5%
Phase 4422.8%
Not applicable100.7%

Most active sponsors

Lead sponsors with the most studies (Kumamoto)
Lead sponsorStudiesRecruiting
AstraZeneca2011
Janssen Research & Development, LLC107
Takeda108
GlaxoSmithKline71
Daiichi Sankyo64
Alexion Pharmaceuticals, Inc.52
Amgen51
Eli Lilly and Company55
AbbVie44
Novartis Pharmaceuticals41
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.